Anthony Bergmann Sells 500 Shares of Capricor Therapeutics (NASDAQ:CAPR) Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 500 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $30.00, for a total transaction of $15,000.00. Following the completion of the sale, the chief financial officer directly owned 11,223 shares in the company, valued at $336,690. This trade represents a 4.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Anthony Bergmann also recently made the following trade(s):

• On Wednesday, June 24th, Anthony Bergmann sold 400 shares of Capricor Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $12,000.00.
• On Friday, May 1st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The stock was sold at an average price of $31.70, for a total value of $792,500.00.
• On Tuesday, March 31st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.13, for a total value of $753,250.00.

Capricor Therapeutics Price Performance

NASDAQ:CAPR traded down $0.09 during trading hours on Wednesday, reaching $29.51. 803,008 shares of the company traded hands, compared to its average volume of 955,468. The firm’s 50-day moving average is $30.26 and its 200-day moving average is $28.40. The stock has a market cap of $1.71 billion, a P/E ratio of -12.72 and a beta of 0.39. Capricor Therapeutics, Inc. has a 1-year low of $4.30 and a 1-year high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.04). As a group, research analysts predict that Capricor Therapeutics, Inc. will post -0.75 earnings per share for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

Several large investors have recently added to or reduced their stakes in the business. KBC Group NV acquired a new stake in Capricor Therapeutics in the 1st quarter worth about $44,000. ACT Capital Management LLC acquired a new position in shares of Capricor Therapeutics during the 4th quarter valued at about $43,000. GoalVest Advisory LLC acquired a new position in shares of Capricor Therapeutics during the 4th quarter valued at about $59,000. Allworth Financial LP lifted its holdings in shares of Capricor Therapeutics by 5,021.5% during the 4th quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 3,264 shares during the period. Finally, State of Wyoming lifted its holdings in shares of Capricor Therapeutics by 76.0% during the 4th quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 1,913 shares during the period. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on CAPR shares. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Monday, June 15th. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Capricor Therapeutics in a report on Wednesday, May 13th. Roth Mkm reissued a “buy” rating and issued a $38.00 price objective on shares of Capricor Therapeutics in a research report on Friday, May 15th. Piper Sandler reissued an “overweight” rating and set a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. Finally, Cantor Fitzgerald set a $62.00 target price on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a research report on Friday, March 13th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.36.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.